CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

Cancer drugs are booming, obesity bets are rising, and a Trump deal just locked in three years of tariff-free growth.

AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings.

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

Virginia will be home to a workforce training center preparing thousands of people each year for a career in the pharmaceutical industry.

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving ...